首页> 外文OA文献 >Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy

【2h】

Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy

机译：接受培美曲塞加卡铂或吉西他滨加卡铂作为一线化疗的晚期非小细胞肺癌患者的TS，TTF-1，FR-α，FPGS与总生存率的相关性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Grønberg Bjørn H.; Lund-Iversen Marius; Strøm Erik H.; Brustugun Odd Terje; Scott Helge;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Associations between TS, TTF-1, FR-alpha, FPGS, and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy [J] . Bjern H. Gronberg, Marius Lund-Iversen, Erik H. Strom, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2013,第10期

机译：TS，TTF-1，FR-α，FPG和晚期非小细胞肺癌患者的总生存期间接受Pemetrexed Plus Carboplatin或Gemcitabine Plus Carboplatin作为一线化疗
2. Associations between TS, TTF-1, FR-alpha, FPGS, and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy [J] . Bjern H. Gronberg, Marius Lund-Iversen, Erik H. Strom, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2013,第10期

机译：接受培美曲塞加卡铂或吉西他滨加卡铂作为一线化疗的晚期非小细胞肺癌患者的TS，TTF-1，FR-alpha，FPGS和总生存率之间的关联
3. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. [J] . Gronberg BH, Bremnes RM, Flotten O Journal of Clinical Oncology . 2009,第19期

机译：挪威肺癌研究小组进行的III期研究：培美曲塞加卡铂与吉西他滨加卡铂作为晚期非小细胞肺癌的一线化疗药物。
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. PRONOUNCE: Randomized Open-Label Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer [O] . Ralph G. Zinner, Coleman K. Obasaju, David R. Spigel, -1

机译：代名词：晚期非鳞状非小细胞肺癌患者一线培美曲塞+卡铂联合维持培美曲塞与紫杉醇+卡铂+贝伐单抗+贝伐珠单抗一线治疗的随机开放标签III期研究
7. PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer [O] . Zinner Ralph G., Obasaju Coleman K., Spigel David R., 2015

机译：方案：对于晚期非鳞状非小细胞肺癌患者，一线培美曲塞+卡铂联合维持培美曲塞与紫杉醇+卡铂+贝伐单抗联合贝伐珠单抗治疗的一线随机，开放标签，III期研究

Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy

著录项

引文网络

相似文献

相关主题

期刊订阅